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Abstract
Introduction: Metastases to the thyroid are revealed at autopsy with a frequency of 2–24%; however, clinically they appear less frequently, 
at 0.1–3%. The aim of the study was analysis of the frequency of revealing metastases to the thyroid (TM) and to the regional lymph 
nodes (NM) (neoplasms other than primary thyroid tumours) in preoperative diagnostics of the thyroid in patients with positive (C+) 
and negative (C–) history of cancer; analysis of ultrasound (US) images of metastases.
Material and Methods: Results of US/fine needle aspiration (FNA) of the thyroid in 1276 C+ patients and 18,947 C- patients.
Results: TM and NM were diagnosed/suspected in 57 patients (0.3% of all examined; 40 TM, 22 NM, 5 both), and their frequency was 
higher in the C+ group (2.9% vs. 0.1% in C–, p < 0.0001). In the C+ group, diagnosis of metastasis accounted for 72.3% of FNA results 
from the category “malignant neoplasm”; in the C– group it was 9.5% (p < 0.0001). The highest relative frequency of TM was found 
for cancers infiltrating thyroid by direct extension (> 10%), lymphomas (7.7%), and kidney (5.3%) and lung (4.9%) cancers. The mean 
age of patients with metastasis (63.9 ± 11.7 years) was similar to that of the C+ group and higher than the C- group (53.9 ± 14.8 years, 
p < 0.0001). The proportion of males among the patients with metastasis was three-fold higher than in the patients without metastasis 
(p < 0.0001). TM lesions presented suspicious borders in US twice as often as primary cancers .
Conclusions: Metastases to the thyroid are rare; however, for patients with a history of cancer, their presence is more likely than primary  
thyroid cancer. US/FNA imaging of metastases allows the selection of patients requiring further diagnostics and treatment.  
(Endokrynol Pol 2015; 66 (6): 495–503)
Key words: thyroid; metastasis; fine needle aspiration biopsy; ultrasound; thyroid cancer
Streszczenie
Wstęp: Przerzuty do tarczycy ujawnia się podczas autopsji z częstością 2–24%, jednak klinicznie stwierdza się je rzadziej: 0,1–3%. Celem 
pracy była analiza częstości ujawniania podczas diagnostyki tarczycy przerzutów do tarczycy (TM) i węzłów chłonnych szyi (NM) 
(nowotworów innych niż pierwotne tarczycy) u osób z dodatnim (C+) i ujemnym (C–) wywiadem nowotworowym; analiza obrazu 
ultrasonograficznego przerzutów. 
Materiały i metody: Wyniki US/FNA tarczycy 1276 osób z grupy C+ oraz 18947 z grupy C-. 
Wyniki: TM lub NM rozpoznano/podejrzewano u 57 osób (0,3% wszystkich badanych; 40 TM, 22 NM, 5 oba), częstość ich ujawniania była 
wyższa w grupie C+ niż C– (2,9% vs. 0,1%, p < 0,0001). W grupie C+ rozpoznania przerzutu stanowiły 72,3% wyników FNA należących 
do kategorii nowotwór złośliwy, w grupie C–: 9,5% (p < 0,0001). Najwyższą względną częstość ujawniania przerzutów stwierdzono dla 
nowotworów naciekających tarczycę przez ciągłość (> 10%), chłoniaków (7,7%), raków nerki: 5,3% i płuca 6,2% (4,9% bez NM). Średni 
wiek pacjentów z przerzutem: 63,9 ± 11,7 lat był podobny do wieku osób z grupy C+ i wyższy od wieku osób z grupy C– (53,9 ± 14,8, 
p < 0,0001). Odsetek mężczyzn wśród osób z przerzutem był 3-krotnie wyższy niż wśród osób bez przerzutu (p < 0,0001). Ogniska TM 
— 2-krotnie częściej niż pierwotnych raków tarczycy miały podejrzane granice w US.
Wnioski: Przerzuty do tarczycy są rzadkie, jednak u pacjentów z dodatnim wywiadem nowotworowym ich obecność jest bardziej praw-
dopodobna niż pierwotnych raków tarczycy. Obraz US/FNA przerzutów umożliwia wyodrębnienie pacjentów wymagających dalszej 
diagnostyki i leczenia. (Endokrynol Pol 2015; 66 (6): 495–503)
Słowa kluczowe: tarczyca; przerzut; biopsja aspiracyjna cienkoigłowa; ultrasonografia; nowotwory złośliwe tarczycy 
The study was supported by the Medical University of Lodz (grant number 503-01/1-153-05).
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Material and methods
The study consisted of a retrospective analysis of the re-
sults of US and FNA of the thyroid performed at a single 
centre in patients referred by physicians of the Endocri-
nology Outpatient Clinic in the years 2000–2013. In that 
period examinations were performed in 20,223 patients, 
including 1276 C+ patients, and 18,947 C– patients. 
The prevalence of FNA results with the diagnosis or 
suspected presence of TM or NM (tumours other than 
primary thyroid cancer — nTC) was determined in both 
groups. In addition, the frequency of obtaining results 
considered as an indication for surgical treatment (i.e. 
malignant neoplasm — MN, suspicious for malignancy 
— SM, and suspicious for follicular neoplasm — SFN) 
was compared between the C+ and C– groups. Then, 
in patients of the C+ group the relative frequency of 
revealing metastases was determined depending on the 
type of malignancy they suffered from. Table I presents 
data on types of malignancy diagnosed in patients of 
the C+ group. Results of histopathological examination 
were also analysed in 4032 patients after surgical treat-
ment of the thyroid, who had been diagnosed at our 
centre. On this basis, part of the cytological diagnoses 
of TM/NM was verified. Tumours infiltrating the thy-
roid by direct extension from neighbouring organs and 
lymphomas were included in the analysis. The details 
on FNA protocol and cytological outcome classifica-
tion at our department were reported previously [20]. 
Surgical thyroidectomy specimens were processed by 
standard procedures. If necessary, immunohistochemi-
cal procedures were applied. 
Ultrasonographic images of TM and NM were 
characterised. In the case of TM the presence of the 
ultrasonographic malignancy risk features (MRFs) 
in metastatic lesion was analysed: solid hypoechoic 
structure, taller-than-wide shape, irregular, blurred 
margin, intranodular vascularisation, and microcalci-
fications. The incidence of these MRFs was compared 
between TM and 250 consecutive benign lesions (BL) 
of the thyroid as well as 105 primary thyroid cancers 
(TC) that were diagnosed at our centre in the same 
period and confirmed histopathologically. In the case 
of NM the presence of ultrasonographic risk features 
for metastasis in the lymph node (NRFs) was analysed, 
such as hypoechogenicity without visible hilum, 
cystic degeneration, presence of calcifications, sus-
pected shape (thickness > 0.5 length), enlargement (any 
diameter > 10 mm), and clustering of nodes. Ultra-
sound examinations were performed with two high-
resolution sonographs (Siemens Elegra Advanced, Sie-
mens Medical Systems, Inc., Issaquah, WA, USA, before 
September 2011, and then Aloka Prosound Alpha 7, 
ALOKA Co. Ltd., Tokyo, Japan). 
Introduction
Secondary tumours of the thyroid may be a conse-
quence of metastasis from distant organs as well as 
infiltration of the gland by tumours from adjacent 
structures. The frequency of revealing such tumours 
is much higher in autopsy studies than in clinical 
studies [1]. This is mainly due to the detection of 
many clinically silent lesions. However, also in the 
autopsy the frequency of metastases varies from 5% 
in the general populations to 10% in patients with rec-
ognised primary cancer, and even to 24% in patients 
with widespread malignancy (including patients 
with lymphomas and tumours infiltrating the thyroid 
by direct extension from the neighbouring organs) 
[2–6]. Some authors, following Willis, suggest that 
the thyroid is protected from the settlement of cancer 
cells through rapid blood flow within the gland, high 
partial pressure of oxygen, and high iodine concentra-
tion [3]. These factors may cause the gland to become 
a place of metastasis only at later stages of generalised 
neoplastic disease.
Metastases to the thyroid are revealed clinically with 
a frequency of 0.1–3% in patients diagnosed or oper-
ated for thyroid nodules/cancer [1, 7–16]. Hegerova et 
al. found metastases in 97 out of 10,798 (0.9%) patients 
identified from a database of cytological material ar-
chived over 30 years at the Mayo Clinic [17]. Wood et 
al. revealed them in 15 out of 1016 (1.5%) patients un-
dergoing surgery for malignant disease of the thyroid 
gland in the period of 17 years [18]. Research carried 
out in Poland by Cichoń et al. brought similar observa-
tions — they revealed 17 cases of secondary tumours in 
10,057 patients operated during 20 years due to thyroid 
disease (0.2%), which accounted for 2.1% of all malig-
nant thyroid neoplasms [19].
It is obvious that the frequency of detection of me-
tastasis to the thyroid depends on the characteristics 
of the examined population, especially in respect to 
the incidence of neoplastic diseases and their clinical 
stage, the age of patients, and the applied diagnostic 
procedures. Therefore, the aim of our study was to 
assess the frequency of revealing metastases during 
the ultrasound (US) and fine needle aspiration biopsy 
(FNA) of the thyroid in patients with thyroid nodules 
(TNs) treated at the endocrine outpatient clinic. In 
addition, a comparison was made of the incidence of 
metastases in patients with positive (C+) and negative 
(C–) history of cancer, and ultrasound images of metas-
tases were characterised. Because US and FNA of the 
thyroid include evaluation of the regional lymph nodes, 
the frequency of revealing metastases to the lymph 
nodes (NM) of other-than-primary thyroid carcinomas 
was also analysed.
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Continuous variables (like the age of patients) were 
analysed with ANOVA and Newman-Keuls tests. The 
comparison of frequency distributions was performed 
with chi-square test (or with Yates corrected chi-square 
test). A value of 0.05 was assumed as the level of sig-
nificance. The study design was approved by the Local 
Bioethics Committee.
Results
The results of FNA, in which the presence of TM or NM 
was diagnosed or suspected, were formulated in 57 pa-
tients (25 males, 32 females), who represented 0.3% of 
all the patients subjected to FNA (Fig. 1). In 40 cases the 
results concerned TM, and in 22 — NM; in five patients 
Table I. Characteristics of malignant tumours occurring in patients with a history of cancer (C +) — localisation of tumours, 
the incidence of metastases to the thyroid or lymph nodes, and sex distribution
Tabela I. Charakterystyka nowotworów złośliwych występujących u pacjentów z dodatnim wywiadem nowotworowym 
(C+) — lokalizacja guzów, częstość ujawniania przerzutów do tarczycy lub okolicznych węzłów chłonnych, dystrybucja 
płci 
Type/Location of the primary 
lesion malignancy
Number/% of all cancers Number/% of men Number/% of patients 
with metastasis*
Number/% of men among 
patients with metastasis
Breast 408/30.8 2/0.5  2/0.5** a 0/0.0
Genitourinary system 383/28.9 78/20.4  11/2.9 b 4/36.4
Reproductive organ 241 –  6/2.5 b –
Prostate 39 39/100.0 1/2.6 1/100.0
Bladder 22 7/31.8 – –
Kidney 76 27/35.5 4/5.3 3/75.0
Others 5 5/100.0 – –
Digestive system 136/10.3 33/24.3  1/0.8 b 1/100.0
Colorectal 124 31/25.0  1/0.8 b 1/100.0
Liver 9 1/11.1 – –
Pancreas 3 1/33.3 – –
Skin 123/9.3 17/13.8 – –
Melanoma 50 4/8.0 – –
Others 73 13/17.8 – –
Head and neck 90/6.8 24/26.7  9/8.9 5/55.6
Salivary gland 19 4/21.1 2/10.5 0/0.0
Larynx 18 10/55.5 2/11.1 2/100.0
Others — Head 16 0/0 1/6.3 0/0.0
Others — Neck 37 10/27.0 4/10.8 3/75.0
Respiratory system (lung) 81/6.1 24/29.6 5/6.2 3/60.0
Blood diseases 60/4.5 14/23.3 4/6.7– 2/50.0
Lymphoid tissue 52 11/21.2 4/7.7 2/50.0
Others 8 3/37.5 – –
Other tumours of the chest and 
abdomen (including tumours of 
unknown origin)
42/3.2 1/11.9 2/4.8 1/50.0
TOTAL 1323/100.0
Number of patients 1276 185/14.5 34/2.7 18/52.9
*three patients were excluded in whom post-operative histological examination revealed papillary carcinoma (2) and non-neoplastic changes following radioiodine 
therapy (1); **in one patient with breast cancer the FNA result revealed metastasis of laryngeal cancer; a — p < 0.0001 vs. those with head and neck cancer;  
b — p < 0.005 vs. those with head and neck cancer
In 45 patients (12 males) two neoplasms occurred at the same time. The most frequent coexistences were the occurrence of breast cancer with cancer of the 
gastrointestinal tract (7), cancer of the reproductive organ (6), lung cancer (4), melanoma (3), and meningioma (2); also occurrence of lung cancer with skin cancer 
(4), bladder cancer with skin cancer (3), kidney cancer with prostate cancer (3) and meningioma (2), and cancer of the reproductive organ with cancer of the 
gastrointestinal tract (2) and skin cancer (2). In one person three tumours coexisted (lung cancer, breast cancer, and melanoma). In other cases a single combination of 
two malignant tumours were observed
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the presence of metastasis was diagnosed/suspected in 
both localisations (TM + NM). In 13 patients cytologi-
cal examination accurately identified the presence of 
metastasis (malignant neoplasm —metastasis: MN-m); 
in 20 patients the result of FNA included diagnosis of 
MN without specifying its histogenesis, but with the 
consideration for metastasis (malignant neoplasm — 
possible metastasis: MN-pM); and in 24 other patients 
it corresponded to SM, also with a suggestion of tak-
ing into account a secondary tumour (suspicious for 
malignancy — possible metastasis: SM-pM) (Fig. 1). In 
37 (64.9%) cases the diagnosis of metastasis related to 
C+ patients, and in the remaining 20 (35.1%) cases — to 
the patients of the C– group. In the C– group the FNA 
result specified the probable source of metastasis in 
one case only (of TM), indicating breast cancer.
Surgical treatment was performed, according to 
medical records, in 25 of 57 patients with metastases. 
Histopathological examination confirmed the presence 
of thyroid malignancy in 23 (92.0%) operated patients, 
and metastasis in 20 of them (13 in the C+ group and 
7 in the C– group) — see Figure 1. In the group of 
20 patients with surgically confirmed metastasis six 
patients (30.0%) had metastasis of renal cell carcinoma 
(3 C+, 3 C–), two had lung cancer (both C+), two had 
salivary gland cancer (1 C+ 1 C–), two had larynx car-
cinoma (2 C+), one had ovarian cancer (C+), and one 
had secondary lymphoma (C+). Six patients (3 C+, 
3 C–) had infiltration of the thyroid by direct extension 
of a tumour from the neighbourhood, including one 
patient with synchronous tracheal cancer and primary 
papillary carcinoma.
The frequency of revealing metastasis was signifi-
cantly higher in the C+ group than in the C– group: 
2.9% vs. 0.1%, respectively, p < 0.0001 (Table II). TM 
was revealed more frequently in the C+ group, while 
NM was observed more frequently in the C– group 
(p < 0.01). In addition, the C+ group was characterised 
by higher incidence of FNA results with an indication 
for surgery (MN, SM, SFN) (p < 0.0001) and the results 
corresponding to the MN category (p < 0.0001). In the 
C+ group, both among results indicating surgery 
and MN diagnoses, the percentage of diagnosed/ 
Figure 1. Characteristics of metastases identified/suspected in 
FNA in patients with a positive (C+) and negative (C–) history 
of cancer
Rycina 1. Charakterystyka przerzutów rozpoznanych/ 
/podejrzewanych w FNA u pacjentów z dodatnim (C+) i ujemnym 
(C–) wywiadem nowotworowym
Table II. Characteristics of patients with positive (C +) and 
negative (C–) history of malignancy, who underwent FNA 
— comparison of all examined patients and patients with 
TM or NM diagnosed/suspected
Tabela II. Charakterystyka pacjentów z dodatnim (C+) 
i ujemnym (C–) wywiadem nowotworowym poddanych 
FNA — porównanie z osobami z rozpoznaniem/podejrzeniem 
przerzutu
All examined patients Study groups p
C+ 
(n = 1276)
C– 
(n = 18 947)
Mean age ± SD 63.8 ± 11.1 53.9 ± 14.8 p < 0.0001
No/% of males 185/14.5% 2235/11.8% p < 0.005
No/% of patients treated 
with 131I
108/8.5% 1023/5.4 p < 0.0001
No/% of patients after 
thyroid surgery
216/16.9% 2842/15.0 NS
No/% of patients with 
FNA result constitutes an 
indication for surgery
91/7.1% 864/4.6% p < 0.0001
No/% of patients with 
cytological diagnosis MN 
47/3.7% 211/1.1% p < 0.0001
No/% of patients 
diagnosed/suspected 
of metastasis (TM, NM, 
TM + NM)
37/2.9% 20/0.1% p < 0.0001
Patients with TM or NM
No of metastases 39 23
No/% of TM 30/76.9% 10/43.4% p < 0.01
No/% of NM 9/23.1% 13/56.6% p < 0.01
Mean age ± SD 64.7 ± 11.2 62.1 ± 12.6 NS
No/% of males 18/48.6% 7/36.8% NS
No/% of patients treated 
with 131I
3/8.1% 1/5.0% NS
No/% of patients after 
thyroid surgery
5/15.6% 4/20.0% NS
TM — metastasis to the thyroid gland, NM — lymph node metastasis (of 
cancer other than primary thyroid cancer)
Diagnosis/suspicion of metastasis in FNA
   57
C+ C–
37 20
TM NM TM+NM TM NM TM+NM
28 7 2 7 10 3
 MN-m (6) MN-m (2) MN-m (1) MN-m (1) MN-m (3) MN-pm (3)
 MN-pm (6) MN-pm (5) SM-pm (1) MN-pm (2) MN-pm (4)
SM-pm (16) SM-pm (4) SM-pm (3)
Surgical treatment
25
C+ C–
16 9
Metastasis (13) Metastasis (7)
Primary papillary thyroid carcinoma (2) Primary undifferentiated thyroid cancer (1)
Benign lesion — after treatment 131I (1) Clear cell adenoma (1)
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/suspected metastases was higher than in the C– group 
(respectively, 40.7% vs. 2.3% and 72.3% vs. 9.5%, 
p < 0.0001 in both cases). 
The mean age of patients in the C+ group was 
significantly higher than in the C– group (p < 0.0001). 
The mean age of patients with diagnosed/suspected 
metastasis was 63.9 ± 11.7 years (mean ± SD, min. 25, 
max. 83) and was similar in both groups and higher 
than the average age of the patients of the C– group 
without metastases (p < 0.001). Among the patients 
with diagnosed/suspected metastasis the percentage 
of males was more than three times higher than in the 
patients without such a diagnosis (p < 0.0001 in both 
the C+ and C– groups). In both the C+ and C– groups, 
the frequency of previous treatment with radioiodine 
or surgery was similar in patients with TM and other 
patients (Table II).
Table I provides data on the relative incidence of 
metastases in patients in the C+ group depending on 
primary tumour origin. The highest relative frequency 
of revealed metastases was observed in patients with 
neck and head cancers (8.9%), and in the case of tu-
mours of the salivary glands, the larynx, and other 
tumours of the neck (mainly tracheal and oesophageal) 
the relative incidence of metastasis exceeded 10%. In 
7 of 9 (77.8%) cases these tumours infiltrated the thyroid 
by direct extension from the neighbouring organs: one 
salivary gland cancer and two cancers of the larynx, the 
trachea, and the oesophagus each. Furthermore, metas-
tases were most frequent in patients with lymphomas 
(7.7 % — only TM), kidney cancer (5.3 % — only TM), 
and lung cancer (6.2 %; after exclusion NM type lesions 
— 4.9%). Metastases to the lymph nodes — without 
involvement of the thyroid — were found in seven 
patients, including six women: four with reproductive 
system cancers (two — ovarian cancer, two — cervical 
cancer), one lung cancer, one breast cancer (but the 
metastasis to the lymph node concerned the cancer of 
the larynx, of which it was the first sign), and in one 
male with unidentified primary origin. 
The mean interval between the diagnosis of can-
cer and revealing TM/NM metastasis was 56.3 ± 65.7 
months (min: 2, max: 240 months). Six patients out of 
57 (10.5%; 4 TM and 2 NM) had symptoms indicating 
the presence of a malignant tumour in the region of 
the neck — hoarseness, swelling, rapid nodule en-
largement. In 27 patients (67.5%) TM was located in 
the enlarged thyroid, and in 31 patients (77.5%) TM 
was one of many lesions/nodules in the gland. Table III 
shows a comparison of the frequency of MRFs in TM 
and lesions corresponding to BL and TC. It was found 
that both primary and secondary malignant tumours 
of the thyroid showed the presence of more than one 
MRF more often than BL. In particular, the TM and TC 
had pathological vascularisation several times more 
frequently than BL; they were two and three times 
more likely to contain microcalcifications, respectively, 
and were more often hypoechoic. TM differed from the 
primary tumours of the thyroid gland, both benign and 
malignant, with more than two-times higher incidence 
of blurred, irregular borders. The smallest lesion of TM 
was 0.17 cm3 in volume, the largest one was 175 cm3; 
due to the blurred borders of the lesions we often could 
not accurately determine the size of the TM. The lymph 
nodes with metastasis in 20 of 22 (90.9%) patients were 
enlarged and hypoechoic. In seven (31.8%) patients 
they formed packets, in six patients (27.2%) they were 
characterised by an irregular shape, in three (13.6%) 
patients they contained calcifications, and in one patient 
(4.5%) they showed features of cystic degeneration and 
had suspected shape.
Discussion
The first description of metastasis to the thyroid gland 
was published in the nineteenth century [1]. Currently, 
the total number of clinically revealed and described 
metastases stands at 1500, but data from individual 
centres typically involve only a few to tens of patients 
Table III. Comparison of the incidence of ultrasonographic 
malignancy risk features (MRFs) in lesions corresponding to 
metastasis to the thyroid gland (TM), benign lesion (BL), and 
primary thyroid cancer (TC)
Tabela III .  Porównanie częstości  występowania 
ultrasonograficznych cech ryzyka złośliwości (MRF) 
w ogniskach odpowiadających przerzutom do tarczycy (TM), 
zmianach łagodnych (BL) i ogniskach pierwotnych raków 
tarczycy (TC)
MRFs No/% p
TM* 
(n = 26)
BL 
(n = 250)
TC 
(n = 105)
Hypoecho-
genicity
26/100.0 177/70.8 95/90.5 p < 0.005 TM vs. BL
p < 0.0001 TC vs. BL
Pathologic al 
vascularisation
13/50.0 23/9.2 55/52.4 p < 0.0001 TM vs. BL
p < 0.0001 TC vs. BL
Blurred, 
irregular 
borders
10/38.5 36/14.4 15/14.3 p < 0.005 TM vs. BL
p < 0.005 TM vs. TC
Micro-
calcifications
8/30.8 36/14.4 48/45.7 p < 0.05 TM vs. BL
p < 0.0001 TC vs. BL
Thickness  
≥ width
4/15.4 24/9.6 18/17.1 p < 0.05 TC vs. BL 
 > 1 MRF 21/80.8 79/31.6 73/69.5 p < 0.0001 TM vs. BL 
p < 0.0001 TC vs. BL 
*included only cases with complete data from ultrasound
500
PR
A
C
E 
O
RY
G
IN
A
LN
E
Metastases to the thyroid Kamila Wysocka et al.
Table IV. Metastases to the thyroid gland in the clinical trials of various centres — publications over the last 20 years dedicated 
to the evaluation of the most frequent location of the primary tumour with at least 10 cases of metastases
Tabela IV. Przerzuty do tarczycy w badaniach klinicznych różnych ośrodków – publikacje z ostatnich 20 lat poświęcone ocenie 
najczęstszej lokalizacji ogniska pierwotnego z minimum 10 przypadkami przerzutów
Authors Country Years Method:
FNA/CNB/HE
No of 
cases
Age 
(mean, min, 
max) (years)
% 
of men
The most  
common  
primary focus
Time to reveal 
metastasis 
(min., max.) 
(months)
Nakhajavani et al. [11] US 1985–1994 FNA/HE 43 66 
47–86
46.5 Kidney 1–312
Lam et al. [3] China 1971–1996 FNA 79 62 
12–94
48.1 Lung 0–84
Chen et al. [9] US 1986–1994 HE 10 58 
48–70
70.0 Kidney 0–234
Wood1 et al. [8] United 
Kingdom
1985–2002 HE 15 63 
26–76
33.3 Kidney 0–180
Kim et al. [12] Korea 1997–2003 HE 22 55 
34–74
27.3 Breast 8–180
Mirallié et al. [27] France 1982–2002 FNA/HE 29 62 
41–78
48.3 Kidney 0–192
Aron et al. [15] India 1982–2002 FNA 24 nd 
28—72
70.8 Continuity/Lung* nd
Cichoń et al. [19] Poland 1984–2003 HE 17 62 
46–76
23.5 Kidney 2–204
Papi et al. [8] Italy 1993–2003 FNA/HE 46 64 
48–89
47.2 Lung nd
Calzolari et al. [13] Italy 1995–2005 HE 25 61 
42–77
56.0 Kidney 0–215
Nixon et al. [44] US 1986–2005 HE 21 68 
39–83
57.1 Kidney 0–195
Hegerova et al. [17] US 1980–2010 FNA/HE 97 60 
22–86
45.4 Kidney, Lung 2–240
Moghaddam et al. [6] US 1993–2013 FNA/HE 10 59 
43–75
30.0 Lung 0–72
Pusztaszeri et al. [14] US/ 
Switzerland 
1992–2014 FNA 62 59 
34–84
45.2 Continuity/
Kidney*
0–156
Romero-Arenas et al. 
[28]
US 2000–2011 FNA/HE 90 61 
28–79
48.9 Kidney 0–210
Yoon et al. [30] Korea 2003–2009 FNA/CNB/HE 23 66.7 
46–85
56.5 Lung 0–192
Our results, this study Poland 1994–2013 FNA/HE 57 64 
25–83
43.9 Continuity/
Kidney* 
0–240
HE — histopathological examination, FNA — fine needle aspiration biopsy, CNB — core needle biopsy; nd — no data; *after exclusion of cases with direct extension 
of tumour from primary lesions in the head and neck and/or lymphomas
(Table 4). It is usually indicated that the primary tumour 
for metastases is located in the kidney, breast, lung, or 
large intestine [1, 7–10, 12–14, 21–23]. However, it is 
difficult to reliably determine which of these tumours 
dominates, due to differences between studied popula-
tions in the incidence of these cancers and the variety 
of diagnostic methods applied to reveal metastases. 
If analysis is based on the results of postoperative 
histopathological examination, it should be taken into 
consideration that not all patients with clinically revealed 
metastasis receive surgical treatment. Early diagnosis 
including a thyroid FNA result allows the avoidance of 
unnecessary thyroid surgery in some cases. On the other 
hand, when analysis is mainly based on biopsy results, 
the limitation is a frequent impossibility to distinguish 
primary, especially non-differentiated, thyroid cancers 
from secondary tumours [11, 14, 23–25]. In such cases the 
FNA result indicates only the need to take into account 
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metastasis in differential diagnosis. However, the current 
indications for biopsy, based on the results of US [26], 
lead to more frequent exposure of metastases in a phase 
when they are clinically asymptomatic. 
Our study relates to patients diagnosed for a thy-
roid disease in an endocrine outpatient clinic, in whom 
a routine ultrasound examination was performed, with 
subsequent biopsy of revealed lesions. Oncological 
patients represented only 6.3% of that population, in 
contrast to centres specialising in the diagnosis and 
treatment of cancers that present many reports on 
metastases to the thyroid gland [13, 27–28]. Probably 
for this reason, in our study the percentage of patients 
with secondary cancer (0.3%) was lower than in typical 
oncological centres, and similar to that found in centres 
involved in the diagnosis of thyroid disorders [15, 25] 
and in general centres (non-specialised) [8] (Table IV). 
Regardless of that fact, our data showed regularity in 
higher risk of metastasis in patients with malignant 
disease than in those with negative history of cancer. 
Moreover, according to our observations, in patients 
with cancer the probability of metastasis in the thyroid 
is more than three-times higher than the probability 
of primary cancer. Similar results were reported by 
Shimaoka et al. [7]. Therefore, in our opinion, the 
appearance of a new nodule in the thyroid in patients with 
(non-thyroid) cancer should be regarded as a potential 
metastasis and considered as an indication for FNA.
Another feature that distinguishes our population 
is a high proportion of women, resulting from the 
epidemiology of thyroid diseases. This affected the type 
of cancer found in our patients — half of them had 
breast cancer or reproductive organ cancer. However, 
these tumours were responsible for only 10% of metasta-
ses to the thyroid gland and/or lymph nodes. In a group 
of over 400 patients with breast cancer metastasis to the 
thyroid gland was found in only two patients (< 1%). 
Similarly, Mirallié et al. (2005) in a group of 29 patients 
with metastasis to the thyroid gland did not find any 
case of breast cancer metastasis [27]. After taking into 
account the relative frequency of metastases (in rela-
tion to the number of patients subjected to FNA with 
a specific cancer) we observed that the dominant type 
of metastases was a tumour infiltrating the thyroid 
by direct extension from the neighbouring primary 
lesion. Also other authors showed that tumours of the 
head and the neck were the most common [14–15] or 
frequent [8] source of metastasis. However, most of the 
authors limited their analyses to metastases from distant 
organs only. They also excluded lymphomas, for which 
it is difficult to judge whether the process is primary 
or secondary. After applying such a model to our data, 
the dominating sources of metastases were kidney and 
lung cancers — as seen in many other reports (Table 
IV). It should be noted that in many published studies 
the influence of the relative frequency of particular 
cancers in an examined population was not analysed. 
Thus, in such studies frequent sources of metastases 
to the thyroid gland also included breast cancer and 
gastrointestinal tract cancers [10, 12, 16]. In our study 
metastasis of malignant tumours of the gastrointestinal 
tract were rare and concerned (like metastasis of breast 
cancer) < 1% of patients with those tumours.
Among patients with metastases the percentage of 
males was much higher (more than 40%) than in the 
group of all patients with cancer (about 15%). It prob-
ably shows a higher predisposition for cancers that 
more readily spread to the thyroid gland among males. 
Actually, cancers of the larynx, lungs, and kidneys are 
significantly more common in males (in Poland: 86%, 
68%, and 58% of cases in 2011, respectively) [29]. But this 
explanation is not complete as the percentage of males 
among patients with metastases of those tumours was 
two-times higher than that among all the patients with 
these tumours subjected to FNA (Table I). Similarly, in 
other studies [14, 17, 28, 30] males constituted 40%–50% 
and even more than 70% [15] of patients with metastasis 
to the thyroid gland. It should also be stressed that the 
percentage of males among patients with secondary 
thyroid tumours was much higher than the percentage 
of males among patients with primary thyroid cancers, 
which in our data was 11% [31].
The mean age of patients with metastases to the 
thyroid gland in our study was 64 years and was higher 
than the average age of all patients referring for FNA 
at our centre, and close to the average age of those 
with a cancer-positive history. Similarly, other authors 
indicate that metastases to the thyroid gland usually 
involve people in the 6th–7th decade of life [8, 11, 14, 
32]. On the other hand, the youngest patient with 
metastasis in our study was 25 years old (infiltration of 
the thyroid was the first sign of cancer), and Pusztaszeri 
et al. showed clear cell sarcoma metastasis in a seven-
year-old child [14].
Our observations and data from other centres in-
dicate that the time lapse from diagnosis of malignant 
disease to revealing metastasis to the thyroid gland 
can be very diverse and can range from a few weeks to 
more than 40 years [9, 11, 13, 18, 33–36]. On the other 
hand, in 35% of our cases metastasis was the first sign 
of cancer. As already mentioned, this was due to the 
routine use of US in all patients with thyroid disease, 
including patients without palpable thyroid nodules. 
Similar data were also presented by other authors (Table 
IV). However, the diagnosis of metastasis to the thyroid 
gland is usually delayed due to the lack of specific 
symptoms. Symptoms such as hoarseness, dyspnoea, 
dysphagia, and rapid enlargement of nodules are rare 
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and uncharacteristic [18]. In our study, only six patients 
presented features of malignant thyroid nodule. In 
the material of the Mayo Clinic only three out of 97 
patients with metastases to the thyroid complained of 
hoarseness, dyspnoea, or rapid growth of the lesion [17]. 
According to the review published by Chung et al., 253 
out of 338 patients presented symptoms such as: new 
or enlarged thyroid nodule, increasing size of the thy-
roid, swelling of the neck, dysphagia, dysphonia, and 
cough [10] — but not all of these symptoms are typical 
of thyroid cancer. Nakhajavani et al. reported that the 
longest period between the diagnosis of the primary 
tumour and metastasis detection was 26 years [11] and 
in a study by Kim et al. it was 15 years. [12]. In both 
of those cases the origin of the metastasis was kidney 
cancer. Other authors also indicate that in the case of 
renal cell carcinoma spreading to the thyroid gland may 
take a long time [14]. In our analysis, similarly, renal 
cell carcinoma was a source of metastasis to the thyroid 
20 years after the initial diagnosis. 
It should be noted that, despite the outlined above 
limits of cytology, FNA allowed the accurate diagnosis 
of metastatic disease in 80.0% of patients in the group 
undergoing surgical treatment, and to formulate the 
suspicion or diagnosis of a malignant neoplasm in as 
many as 92% of those patients. Similarly, other authors 
indicate that FNA did not always accurately diagnose 
metastatic disease, but it identified a thyroid malig-
nancy in approximately 90% of cases [8, 14–15, 37–39]. 
Clinical data about the occurrence of cancer in a patient 
can help in precise cytological diagnosis [14, 25]. In 
the absence of such data the result usually suggests 
suspicion or diagnosis of malignant tumour - as in our 
material in the C– group.
In some publications attention is drawn to the pres-
ence of metastases particularly in patients with mor-
phological changes within the gland [10, 16, 34]. In our 
material approximately 80% of the metastases were one 
of many nodules in the gland, accompanied by other 
focal lesions. In one case postoperative histopathologi-
cal examination revealed the concurrent occurrence of 
papillary thyroid carcinoma and secondary squamous 
cell carcinoma. Similarly, Young et al. published a case 
of a patient diagnosed with both papillary thyroid 
cancer and metastasis of prostate cancer [40]. Interest-
ingly, Hashimoto et al. revealed metastasis of lung 
adenocarcinoma to the follicular variant of papillary 
carcinoma [41], and Kameyama et al. and Pusztaszeri 
et al. described metastases to follicular adenoma [14, 
42]. It is possible that the presence of thyroid pathology 
facilitates tumour cells settlement in the thyroid gland. 
Moreover, it is suggested that even disruption of the 
thyroid tissues, changes in blood flow in the gland, or 
changes in the intrathyroid iodine concentration may 
promote the formation of secondary tumours [12]. Our 
data showed no significant relationship between previ-
ous thyroid surgery or radioiodine treatment and the 
incidence of metastasis in the thyroid. 
We found that metastases more often than primary 
thyroid tumours had irregular and blurred margins. 
In addition, similarly to primary thyroid cancers and 
more often than benign lesions, metastases had more 
than one ultrasonographic risk feature of malignancy. 
In the literature the typical ultrasound image of sec-
ondary tumours is not specified. The most commonly 
reported are heterogeneous, hypoechoic lesions with 
blurred margins, often with calcifications [23] or without 
them [30]. In our material metastatic tumours presented 
calcifications twice as often as benign lesions, while 
primary tumours showed calcifications three times 
more often than benign lesions. It should be noted 
that initially metastatic lesions have no characteristic 
clinical manifestation and ultrasonographically may 
be similar to frequent benign thyroid nodules. The 
lymph nodes with metastases were characterised by 
enlargement, hypoechogenicity, heterogeneity of the 
structure, the presence of calcification, and a tendency 
to create packages. These are features similar to those 
described in lymph nodes with primary thyroid cancer 
metastases [43].
In conclusion, metastases to the thyroid gland are 
rare. However, for patients with a history of cancer, 
their presence is more likely than primary thyroid 
cancers. The probability of revealing metastases during 
diagnostics of the thyroid is highest in patients with 
neighbouring cancers that may invade the thyroid by 
direct extension, as well as in patients with lymphoma 
and cancers of the lung or kidney. Less frequently 
metastases to the thyroid are found in patients with 
breast or colorectal cancer. It should be emphasised that 
the ultrasound and cytological image of metastases is 
not specific, but it usually allows the identification of 
patients requiring further diagnostics and treatment.
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